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ABSTRACT
Polysomal messenger RNA (mRNA) populations
change rapidly in response to alterations in the
physiological status of the cell. For this reason,
translational regulation, mediated principally at
the level of initiation, plays a key role in the
maintenance of cellular homeostasis. In an
earlier translational profiling study, we followed
the impact of rapamycin on polysome re-seeding.
Despite the overall negative effect on transcript
recruitment, we nonetheless observed that
some mRNAs were significantly less affected.
Consequently, their relative polysomal occupancy
increased in the rapamycin-treated cells. The
behaviour of one of these genes, mdm2, has been
further analysed. Despite the absence of internal
ribosome entry site activity we demonstrate,
using a dual reporter assay, that both the reported
mdm2 50-UTRs confer resistance to rapamycin
relative to the 50-UTR of b-actin. This relative resist-
ance is responsive to the downstream targets
mTORC1 but did not respond to changes in the
La protein, a reported factor acting positively on
MDM2 translational expression. Furthermore,
extended exposure to rapamycin in the presence
of serum increased the steady-state level of
the endogenous MDM2 protein. However, this
response was effectively reversed when serum
levels were reduced. Taken globally, these
studies suggest that experimental conditions can
dramatically modulate the expressional output
during rapamycin exposure.
INTRODUCTION
Studies suggest that the differential recruitment onto
polysomes of messenger RNA (mRNA) populations
may be sufﬁcient to initiate and maintain tumour forma-
tion (1). Nonetheless, the rules that govern these events
remain largely unresolved. Translation is regulated princi-
pally at the step of initiation (i.e. mRNA recruitment onto
polysomes). One of the key targets for this regulation is
the cap binding protein eukaryotic initiation factor 4E
(eIF4E). It is frequently rate limiting (2), and can also
be sequestered into an inactive complex by a family of
4E-binding proteins (4EBP1/2/3). The afﬁnity of these
proteins for eIF4E is modulated by phosphorylation
in response to cell growth signals. This releases eIF4E
increasing its availability for the formation of the
active cap binding complex, eIF4F (3). The phosphor-
ylation event is mediated by the PI3K/AKT pathway
that impacts on translation initiation via mammalian
target of rapamycin (mTOR) (4–6). This kinase exists
within two distinct complexes referred to as complex 1
(mTORC1) and complex 2 (mTORC2). The best-
characterized downstream effectors of the mTORC1,
namely, the 70-kDa ribosomal protein S6 kinase 1
(S6K1) and the 4EBP1 pathways, act in parallel to
regulate mRNA translation (7–9).
Because of its cardinal role in cell growth regulation, a
great deal of research has been directed towards the
development of mTOR inhibitors for cancer therapy
(10,11). One of these, rapamycin, exerts its action by
binding and inactivating the mTORC1 via its RAPTOR
subunit (11–13) which, in turn, leads to a global
down-regulation of protein synthesis. Recently, we
reported on the impact of rapamycin on the re-seeding
of the polysome populations in the non-tumoural cell
line MRC-5. We identiﬁed transcripts that exhibited
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altered sensitivities to the drug, thus creating a molecular
signature within this cellular context and growth condi-
tions (14). One of the genes whose relative polysomal
occupancy increased was mdm2. Its most-studied
function is the regulation of the tumour suppressor
protein P53. The mdm2 gene is transcribed from two
promoters: the upstream promoter (P1) ensures constitu-
tive expression and a second downstream promoter (P2) is
activated by P53 (15). This serves as an auto-regulatory
feedback loop in which P53 modulates the expression of a
protein that inhibits its own function. The two mdm2 gene
promoters generate mRNA transcripts with different
50-UTRs. The longer, P1-derived 50-UTR (L-mdm2),
possesses two upstream open reading frames (ORFs)
which repress translational initiation from the MDM2
start codon. The shorter P2-derived 50-UTR (S-mdm2)
carries no such elements and is generally translated more
efﬁciently. The probe sets used in our original microarray
were 30 on the mRNA and so were unable to distinguish
between the two 50-UTRs. An additional problem
associated with studying mdm2 gene expression arises
due to the complexity of the alternatively spliced
transcripts. At least 40 such variants have been reported.
The p90 full-length protein is frequently detected with
other isoforms (generally p85, p75, p57 and p46), which
retain part(s) of the P53 binding site and nuclear
import/export signals. However, one feature shared by
all spliced forms is the presence of either the L-mdm2 or
S-mdm2 50-UTR.
In this work, we have examined the role of the two
50-UTRs in the rapamycin resistance associated with the
polysomal recruitment of the mdm2 transcript. We have
been unable to detect discernable internal ribosome entry
site (IRES) activity in either of the alternative 50-UTRs.
Nonetheless, both regions confer relative drug resistance
in a dual reporter assay performed in HEK293T cells.
Results indicate that this is associated with alterations
in the downstream mTORC1 targets. Furthermore,
extended rapamycin exposure under conditions of high
serum (conditions under which our earlier studies were
performed) results in an increase in the steady-state
levels of the endogenous MDM2 protein in both
HEK293T and MRC-5 cell lines. However, this response
is effectively reversed when serum levels are reduced.
Taken globally, these studies suggest that the cellular con-
text and experimental conditions can dramatically
modulate the 50-UTR-mediated expressional output
during rapamycin exposure.
MATERIALS AND METHODS
Cell culture
HEK293T cells (ATTC, CRL-11268) were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Sigma)
supplemented with 10% fetal calf serum (Brunschwig),
1% penicillin/streptomycin (Gibco), in a humidiﬁed at-
mosphere containing 5% CO2. MRC-5 cells (Coriell Cell
Repository) were cultured in Minimal Essential Medium
(Gibco) supplemented with 1mM sodium pyruvate
(Sigma), 0.1mM non-essential amino acids, 10% fetal
calf serum, 1% penicillin/streptomycin, in a humidiﬁed
atmosphere containing 5% CO2. HCT116 cells were
obtained from Dr Andre´ Fedier (University Hospital
Zurich, Department of Gynecology) and were cultured
in McCoy’s 5A medium (Sigma) supplemented with
10% fetal calf serum, 1% penicillin/streptomycin.
Rapamycin was purchased from LC laboratories and
stored as a 50-mM stock in dimethyl sulphoxide
(DMSO) at 20C.
DNA constructions
The bicistronic clones were generated in a pcDNA3
backbone. The 50-UTRs were inserted into the
intercistronic region as XhoI/NcoI fragments produced
by reverse transcription-polymerase chain reaction
(RT–PCR) from total cell RNA as outlined in (14). The
encephalomyocarditis virus (EMCV) IRES construct has
already been described (16). The primer sets used were as
follows:
QKI: GTCGAGCTCCATGGATTCCAGGCTCCGCA
GCTCACT, CCGCTCGAGTGAACTGAGGCGAA
CTCCGCC
THAP2: TCGAGCTCCATGGCCCTTTCCCACTCAT
TCAGCGCCC, CCGCTCGAGACTTCCTGCGACA
CGCAGGAAACA
FAS: CGGGATCCATGGGGTTGTTGAGCAATCCT
CCGAAGT, CCGCTCGAGTCTGTGAGCCTCTCA
TGTTGCA
FASL: GTCGAGCTCCATGGGGCAGCTGGTGAGT
CAGGCCAGCC, CCGCTCGAGAGAATCAGAGA
GAGAGAGATAG
FAF1: GTCGAGCTCCATGGGGGCGGCCGCCGAG
TTCCGCGGCT, CCGCTCGAGCAGGGGCGGAG
GCGGCGGCCA
L-MDM2: GTCGAGCTCCATGGTTGCCTGCTCCTC
ACCATCCGGGGT, CCGCTCGAGCCGAGGCAC
CGCGGCGAGCTT
S-MDM2: Was generated as two overlapping primers
carrying XhoI and NcoI extremities.
VCME: CATGCCATGGCGAATTCCCCCTCTCC, CC
GCTCGAGCGCGTGTTTTTCAAAGGAAAACC
The pGL3-Enhancer monocistronic vector carrying the
human b-actin 50-UTR and the RLuc reporter was
generated by RT–PCR cloning the former from
HEK293T total cell RNA, and amplifying the latter
from the bicistronic plasmid clone. The primers used are
listed below. The fragments were subsequently ligated and
then used to replace the original FLuc reporter in the
plasmid.
b-Actin: CCGAAGCTTCGCGTCCGCCCCGCGAGCA
CAGA, CACCATGGTGGCTAGCGGTGAGCTGG
CGGCGGGTG,
RLuc: GCCACCATGGCTTCGAAAGTTTTTG, GCC
TCGAGTTATTGTTCATTTTTGTG
The plasmid expressing the siRNA against RLuc (pBS/
U6-RLi) and the empty vector control (pBS/U6ApaI)
were supplied by Dr Richard Lloyd (Houston, USA).
The Flag-La, GSTLa226-348 and eIF4E plasmids were
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provided by Dr. Nahum Sonenberg (Montreal, Canada).
The 4EBP1 expressing plasmid was provided by Dr. Chris
Proud (Southampton, England). The His/myc tagged
S6K1 constructs were provided by Dr. George Thomas
(Cincinnati, USA).
Fireﬂy reporter assays
Calcium phosphate-mediated DNA transfection was
performed as described in ref. 17. Transfections were
performed in triplicate. Rapamycin was applied as
indicated in the ﬁgure legends. Extracts were prepared in
passive lysis buffer according to the supplier (Promega).
The activity of ﬁreﬂy (FLuc) and renilla (RLuc) luciferases
were measured using the dual-luciferase reporter assay
system (Promega) on a Gloma 20/20 luminometer
(Promega).
Western blot
Cytoplasmic extracts were prepared by solubilizing the
monolayer in 150mM NaCl, 50mM Tris–HCl pH 7.4,
10mM EDTA, 0.6% NP-40, and the complete
mini protease inhibitor cocktail (Roche). Nuclei were
removed by pelleting at 20 000g for 5min. Thirty
micrograms of protein was resolved on a
polyacrylamide-sodium dodecyl sulphate (SDS) gel and
electro-transferred to polyvinylidene ﬂuoride (PVDF).
Antibodies used in this study were anti-MDM2 (2A10,
Calbiochem), anti-actin (Chemicon), anti-4EBP1 (Cell
Signalling), anti-eIF2a (Cell Signalling), anti-phospho-
eIF2a (Invitrogen), anti-eIF4E (Cell Signalling), anti-P53
(PAb240, Calbiochem), anti-phospho S6K1 (Cell
Signalling), anti-Flag (polyclonal, Sigma-Aldrich),
anti-Myc (9E10, Covance) and anti-ELK1 (Santa Cruz).
A polyclonal rabbit anti-GST antibody was kindly
provided by Dr. Dominique Soldati-Favre (Geneva,
Switzerland). Blots were developed using the Super
Signal Substrate (Thermo Scientiﬁc) and quantitated
using the Quantity One software package (Bio-Rad).
Pulse-chase experiments
For protein labelling, cells were starved for 30min in
DMEM minus methionine and cysteine (Gibco). This
was then replaced with the same medium containing
100 mCi/ml 35S-translabel for 1 h (Amersham). For the
chase period, the labelling medium was removed and
replaced with normal growth medium containing 10%
serum (with either DMSO or rapamycin) for the times
indicated. Cytoplasmic extracts were prepared by
solubilizing the monolayer in 150mM NaCl, 50mM
Tris–HCl pH 7.4, 10mM EDTA, 0.6% NP-40, 1mM
AEBSF (Boehringer) and 1% aprotinin (Sigma). Nuclei
were removed by pelleting at 20 000g for 5min. Extracts
were immunoprecipitated overnight at 4C with 2.5 vol. of
RIPA buffer (150mM NaCl, 1% deoxycholate, 1%
Triton X-100, 0.1% SDS, 10mM Tris pH 7.8) containing
the MDM2 antibody 2A10. The immune complexes were
recovered on protein-A Sepharose (Pharmacia) for 1 h
at room temperature (RT), washed three times with
RIPA buffer. Samples were boiled with sample buffer
(10% glycerol, 5% b-mercaptoethanol, 2.5% SDS,
60mM Tris–HCl pH 6.8, bromophenol blue) and
proteins were resolved by SDS–polyacrylamide gel electro-
phoresis (PAGE).
RT–PCR and real-time PCR
The RT–PCR was performed using the One Step
RT–PCR kit (Qiagen) according to the manufacturer’s
instructions. The number of ampliﬁcations cycles was
ﬁrst determined for each set of primer, and corresponded
to the exponential phase of the different products (16).
For the semi-quantitative RT–PCR on the reporter
transcripts, the ﬂowing primer sets were used:
L-mdm2 FLuc: CCGAGGCACCGCGGCGAGCTT, GC
TCTCCAGCGGTTCCATCTTCCAG
S-mdm2 FLuc: GGGCACGGACGCACGCCACTTT, G
CTCTCCAGCGGTTCCATCTTCCAG
b-Actin RLuc: CTGACGGCCAGGTCATCACCATTG,
GAGGCCATGATAATGTTGGACGACG
For the real-time PCR, 1 mg of total RNA was reverse
transcribed using random hexamers (Gibco). A 1/10
dilution of the cDNA was used to perform the PCR
with the SYBR Green Reagent (Roche). The primers
used were:
L-mdm2: CCCGACTCCAAGCGCGA, GGTGACACC
TGTTCTCACTCACAGA
S-mdm2: GGGCACGGACGCACGCCACTTT, GGTG
ACACCTGTTCTCACTCACAGA
b-Actin: CTGACGGCCAGGTCATCACCATTG, GCC
GGACTCGTCATACTCCTGCTTG
Polysome analysis
Cells in the growth phase were hypertonically shocked by
shifting to medium containing 300mM NaCl for 50min.
The cells were then placed in normal isotonic medium for
30min. When rapamycin was used, 100 nM drug or 0.01%
DMSO (the negative control) was added during the hyper-
tonic shock, 20min before the transfer back to isotonic
conditions. Rapamycin and DMSO were kept on the
cells throughout the recovery period. After treatment,
cells were scraped into the culture medium and pelleted
for 4min at 800 r.p.m. The pellets were lysed for 15min on
ice in 100mM KCl, 50mM Tris–Cl pH 7.4, 1.5mM
MgCl2, 1mM DTT, 1mg/ml heparin, 1.5% NP-40,
100 mM cycloheximide, 1% aprotinin, 1mM AEBSF and
100U/ml of RNasin. Nuclei were pelleted by centrifuga-
tion, 10min at 12 000 r.p.m. The supernatant was loaded
on a 20–60% sucrose gradient (in 100mM KCl, 5mM
MgCl2, 20mM HEPES pH 7.4 and 2mM DTT).
Extracts were fractionated for 3 h 30min at 35 000 r.p.m.
at 4C in a Beckman SW41 rotor. The gradient was
analysed and the fractions collected with the ISCO UA-6.
RNA was isolated by adding the same volume of TriZol
(Invitrogen) to the fractions. Samples were mixed and
incubated for 15min on ice, and 0.3 vol of chloroform
was added. After centrifugation, the upper phase was
collected and the RNA precipitated with 0.7 vol of isopro-
panol. The pellet of RNA was re-suspended in water.
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RESULTS
Translational properties of the mdm2 50-UTR
The starting point for the current study was a
high-throughput translational proﬁling screen that
followed ribosome-transcript re-association in the
presence and absence of rapamycin (14). Data mining
revealed that the relative polysomal occupancy of 3.6%
of the transcripts was affected by the drug. One feature
that could impact on the sensitivity to rapamycin is the
presence of an IRES within the 50-UTR. We therefore
tested for the presence of such an element in six different
genes, three that were up-regulated (qki, mdm2 and thap2)
and three that were down-regulated (fas, fasl and faf1).
Surprisingly, the results indicated that 50-UTRs both
from the up and down-regulated sets, had normalized
second cistron activities signiﬁcantly higher than
the VCME negative control (Figure S1A). However, the
bicistronic assay is not sufﬁcient to unambiguously deﬁne
an IRES (18–22), and further controls indicated that all
constructs, with the exception of mdm2, presented signiﬁ-
cant cryptic promoter activity (Figure S1B).
Despite the low activity of the mdm2 50-UTR in the
bicistronic assay, we considered that the result warranted
further investigation. However, the expression of the
mdm2 gene is complex. There are at least 40 alternatively
spliced transcripts and two 50-UTRs. The form we tested
above was the constitutively expressed long form
(L-mdm2) driven from the P1 promoter (Figure 1A).
A second shorter 50-UTR, the S-mdm2, arises from a
second p53 responsive P2 promoter (Figure 1A).
Semi-quantitative RT–PCR analysis conﬁrmed that both
50-UTRs were present in HEK293T (Figure 1B) and
MRC-5 (Figure S2B) cell lines, and there relevant abun-
dance was essentially unaltered following rapamycin
exposure. When tested in the bicistronic assay, the
S-mdm2 gave second cistron activities higher than the
L-mdm2; however, it also had signiﬁcant cryptic
promoter activity (Figure 1C and D). Furthermore,
promoter activity within both the 50-UTRs of S-mdm2
and qki was conﬁrmed by co-transfection of a siRNA
directed against the RLuc ﬁrst cistron (Figure 1E) (18).
Therefore, in a ﬁnal attempt to assign IRES activity to the
L-mdm2, we tested the bicistronic construct in the
presence of rapamycin or 4EBP1 (His/myc tagged). The
over-expression of 4EBP1 has been demonstrated to
down-regulate cap-dependent, but not IRES-driven,
translation. (23). As IRES controls, we also tested the
viral IRES EMCV and a reported cellular IRES Dap5
(24). Consistent with its inhibition of the mTORC1
kinase, rapamycin treatment increased the levels of en-
dogenous hypophosphorylated 4EBP1 (Figure 1G) and
stimulated relative second cistron activity in the EMCV
construct (Figure 1F). However, the effect on both the
L-mdm2 and Dap5 constructs was negative (Figure 1).
Furthermore, whereas 4EBP1 expression had a marked
positive effect on the viral IRES, its effect was once
again negative with both cellular 50-UTRs (Figure 1F
and H). One curious observation in the 4EBP1 transfected
cells was a marked shift to the hyperphosphorylated forms
of the endogenous 4EBP1 (Figure 1H; as if the cell is
desperately trying to detour the 4EBP1 block by activating
mTOR).
The mdm2 50-UTRs and rapamycin
As none of the results unambiguously suggested IRES
activity within the mdm2 50-UTRs, we asked if the
50-UTRs alone conferred relative rapamycin resistance to
a monocistronic reporter. For this, we generated FLuc
constructs carrying either the L-mdm2 or S-mdm2
50-UTRs. As a control, we fused the 50-UTR of the
b-actin housekeeping gene to RLuc because the relative
polysomal occupancy of this mRNA was not affected
by rapamycin in the microarray screen (14) and its expres-
sion is considered a paradigm of 50- cap-dependent
translation (25). The RLuc/FLuc constructs were
co-transfected into cells in the presence or absence of the
drug. Examination of reporter activity 24 h
post-transfection revealed that both the mdm2 50-UTRs
conferred resistance relative to b-actin (Figure 2A).
Semi-quantitative RT–PCR performed on RNA isolated
from these cells demonstrated that rapamycin treatment
reduced transcript levels from all reporter plasmids
equally, indicating that the observed changes in the
normalized values reﬂects a translational response
(Figure 5C; values obtained in 10% serum). Dosing the
concentration of rapamycin from 100 to 0.1 nM
demonstrated that this response correlated with the
activity of mTORC1 as monitored by the phosphorylation
status of 4EBP1 (Figure 2B). This conﬁrms the microarray
results, despite the fact that in the earlier experiments we
followed mRNA-ribosome re-association following short
drug exposure (50min). However, we could not mimic the
effect of the drug by simply over-expressing tagged
versions of 4EBP1 (Figure 2A), despite the fact that this
tends to repress cap-dependent initiation (23). This
suggests that the effect cannot simply be explained by
competitive advantage under conditions of limiting
eIF4E availability. It has been reported that the
rapamycin effect of 4EBP1 activity is temporally regulated
implicating a second cellular kinase (26). However, the
drug-induced enhancement from the mdm2 constructs
remained essentially unchanged between 4 and 48 h
post-transfection (Supplementary Figure S3), an observa-
tion that once again suggests that the effect is not princi-
pally via 4EBP1 and hence eIF4E availability.
As rapamycin is thought to act mainly via the inactiva-
tion of mTORC1 kinase activity, we asked if we could
reverse the rapamycin effect by co-expressing active
versions of its downstream targets. For this we selected
eIF4E, S6K1 T389E and the S6K1 T389A control.
The T389E mutation mimics mTORC1-mediated phos-
phorylation rendering the S6K1 more active under basal
conditions, and partially rapamycin resistant. The T389A
mutant has essentially the opposite effect (27,28).
With S-mdm2, we again observed the positive effect of
rapamycin on the normalized reporter value
(Figure 3A). This was reversed upon over-expression of
T389E but less so by eIF4E. Co-expression of both
reduced levels to below the rapamycin minus control.
In addition, the presence of the S6K1 T389A accentuated
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the effect of the drug on the normalized reporter activities.
With the L-mdm2 construct, the results were very similar
(Figure 3B). One noticeable exception was that the S6K1
T389A construct had only a marginal effect on the readout
hinting at possible differences in the regulation of the two
50-UTRs. Nonetheless, these results appear to conﬁrm that
the relative drug resistance associated with the mdm2
50-UTRs is coupled to mTORC1 signalling.
The MDM2 protein in HEK293T cells
It has been reported that rapamycin treatment can impact
on the intracellular levels of MDM2. Indeed, in our
HEK293T cells, we observed that protein levels increased
after rapamycin exposure (Figure 4A). This increase could
not be attributed to changes in mRNA levels (Figure 4B),
suggesting that it was translational. That the drug had
impacted on mTORC1 signalling was conﬁrmed by
analysing the phosphorylation status of S6K1
(Figure 4A). To further characterize the speciﬁcity of the
rapamycin response, we analysed the expression of other
regulatory proteins in these extracts; namely, ELK-1,
eIF4E and p53 (Figure 4A). Whereas ELK-1 and eIF4E
levels were reduced by the drug (the effect being more
pronounced with the former), P53 was not perturbed.
Changes in the steady-state MDM2 protein without a
concomitant impact on P53 levels have been reported by
others (29).
We also examined if rapamycin altered protein stability.
MDM2 is generally considered to be an unstable protein
at least in part due to its self-polyubiquitinylation (30).
Furthermore, its half-life in certain cell lines has been
reported to be reduced in the presence of rapamycin
(31). However, pulse-chase experiments in HEK293T
cells demonstrated no change in protein turnover as a
consequence of drug exposure (Figure 4C).
The measured t1/2 (2.5 h) was very similar to that
reported recently by others in the same cellular back-
ground (32).
Initiation from both murine 50-UTRs has been reported
to be up-regulated by the La auto-antigen (33). An La
binding site was mapped upstream of the murine
MDM2 AUG codon within the exon II conserved in
both long and short forms. Despite the fact that the
human exon II is removed in the L-mdm2 isoform
(Figure 1A), alignment suggested a similar sequence was
partially conserved in both human 50-UTRs. (33).
Furthermore, a recent microarray study suggested that
La-mediated recruitment of mRNA populations onto
polysomes was coupled to its phosphorylation mediated
via AKT (34). As the PI3K/AKT pathway is tightly
coupled to mTOR, we decided to examine if La expression
could provide insights into the behaviour of the human
50-UTRs in the presence of rapamycin. We obtained an
N-terminally FLAG tagged human La clone, and a GST
tagged deletion mutant (GST-La226-348) which retains
the La oligomerization domain and is dominant negative
for the La-mediated stimulation from the murine mdm2
(35,36). These were transferred to the mammalian expres-
sion vector pEBS-PL, which expresses EBNA1 and carries
an EBV oriP (37). This ensures that the plasmid is retained
in dividing cells. Forty eight hours after transfecting
the La constructs, the cells were re-transfected with the
actin/mdm2 dual reporters and rapamycin was applied.
Extracts were analysed 24 h later. This approach ensured
high levels of La expression at the moment of reporter
gene transfection and drug treatment. This was conﬁrmed
by immunoblotting (Supplementary Figure S4A).
However, we observed no effect on our dual reporter
assay in the presence of rapamycin (Supplementary
Figure S4B; results obtained with the L-mdm2 were iden-
tical). Furthermore, the observed increase in cellular
MDM2 protein levels after rapamycin exposure was not
perturbed by the over-expression of the dominant negative
GST-La226-348 (Figure 4A).
What modulates the mdm2 response?
Although the increased levels of endogenous MDM2
protein observed after extended exposure to rapamycin
would not be inconsistent with our reporter assays, it
does ﬂy in the face of other work. Using a cancer model
system (the HCT116 cell line), it was reported that
rapamycin decreased MDM2 levels by translational inhib-
ition (38). However, this was also at conﬂict with other
results that reported a down-regulation of MDM2 levels
in an OVCAR-3 cell line exclusively by changes in protein
half-life (31). Upon analysis of the results reported in the
HCT116 cell line, we noted that the conditions employed
were somewhat different. Whereas during rapamycin
exposure we maintained serum concentrations at 10%,
the HCT116 work reduced the serum to 2%. They also
employed a rapamycin concentration 10-fold higher
(1 mM). In HEK293T cells, concentrations as low as
1 nM were sufﬁcient to inhibit downstream signalling
from mTORC1 as monitored by 4EBP1 phosphorylation
(Figure 2B, lower panel). In a similar vein, a rapamycin
dose experiment using the mdm2/b-actin reporter assay
demonstrated that the mdm2 50-UTRs conferred relative
resistance at drug concentrations as low as 0.1 nM
(Figure 2B, upper panel). Therefore, we repeated our
HEK293T experiment at two serum concentrations.
Analysis of MDM2 levels 24 h post-drug exposure
demonstrated a striking difference in the response
Figure 1. Continued
set at 1. (E) As a further control the bicistronic constructs were co-transfected with a plasmid expressing either the siRNA against RLuc (pBS/
U6-RLi) or the empty vector control (pBS/U6ApaI). Reporter activity in the cell extracts was measured 24 h post-transfection. The graph plots
reporter activities in the presence of the siRNA RLuc relative to the empty vector control. A value of 1 indicates no change. (F–H) Bicistronic clones
carrying the EMCV, L-mdm2 or Dap5 intercistronic regions were expressed in HEK293T cells in the presence of either DMSO (CTRL), rapamycin
(100 nM added to the growth medium 30min before transfection), or a second vector expressing a His/myc tagged 4EBP1 (co-transfected with the
bicistronic construct). Cell extracts were prepared 24 h post-transfection. Normalized reporter activities were plotted (F) with the control (bicistronic
alone) for each construct being set at 100. Rapamycin activity was conﬁrmed by immunoblotting with an anti-4EBP1 antibody (G), as was expression
of the tagged 4EBP1 transgene (H). Bars indicate the SEM from triplicate transfections.
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(Figure 5A). In the presence of 2% serum, rapamycin
reduced MDM2 levels. In addition, reducing serum
levels in the absence of the drug tended to mimic the
rapamycin effect observed under high serum concentra-
tions (compare lanes 1/3 with lanes 1/2). We asked if
serum concentrations impacted on the readout from the
dual reporter assay. Only a very marginal change was
observed when the serum was reduced to 2% (compare
Figure 5B with Figure 2A); however, the effect was sig-
niﬁcantly attenuated when the assay was performed under
serum-free conditions (Figure 5B). Once again, RT–PCR
analysis demonstrated that although rapamycin impacted
on transcription at all serum concentrations tested, it was
equally repressive for the entire reporter construct set
(Figure 5C), indicating that the observed changes in the
readout reﬂected alterations at the translational level. The
absence of a marked effect on the reporter readout at 2%
serum, despite a clear impact on intracellular MDM2
protein levels in the same cells, suggests that other
elements in the mature mdm2 mRNA may also, in con-
junction with the 50-UTRs, ﬁne-tune the serum response.
Reports on both the human and murine genes indicate
that the 30-UTRs do not affect translational efﬁciency
(39,40), suggesting that elements within the ORF itself
may modulate the response. Regulatory elements within
the ORF of an mRNA that respond to growth and stress
signalling pathways have already been reported (41,42).
The serum effect observed with the S-mdm2 50-UTR
was more marked than that observed with the L-mdm2.
An explanation for this becomes apparent if one examines
how the normalized reporter activities responded to
changes in serum concentrations alone (i.e. in the
absence of the rapamycin: Figure 6A). The increase in
the normalized reporter readout observed with the
L-mdm2 in the absence of serum probably reﬂects
changes in eIF2a activity that arise during these stress
conditions (43), coupled to the presence of uORFs
uniquely in the L-mdm2 50-UTR (but neither in S-mdm2
or b-actin) (44). This interpretation is supported by the
observation that mutation of the two uAUGs to GCG
codons ablated the serum response (Figure 6A). It
should also be noted that these mutations did not alter
the relative rapamycin resistance observed in the dual
reporter assay (Figure 6B), indicating that this phenomena
is not coupled to translational re-initiation.
Despite the fact that one can extract useful information
using values normalized to an internal control, the results
can nonetheless be misleading. This is highlighted in
Figure 5D, in which the rapamycin/serum response of
the S-mdm2 and b-actin reporters (the normalized values
depicted in the right-hand panel of Figure 5B) have been
analysed independently. One observes that expression
from the S-mdm2 reporter is clearly less sensitive to the
drug in the presence of serum (the 2.5-fold difference
corresponds to that observed with the normalized
values) but becomes as sensitive as the b-actin reporter
when serum is removed.
A re-recruitment polysomal assay in HEK293T cells
conﬁrms relative drug insensitivity
The starting point for this work was a high-throughput
analysis of the impact of rapamycin on polysomal seeding
in a human primary cell line MRC-5 (14). Studies focusing
on the role of the 50-UTRs were performed in HEK293T
cells for purely technical reasons (they transfect well);
nonetheless, these studies led to the demonstration of
enhanced MDM2 protein levels after extended exposure.
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Figure 2. Both mdm2 50-UTRs confer relative rapamycin resistance to
a monocistronic construct. (A) pGL3-Enhancer constructs carrying
either the L-mdm2 or S-mdm2 50-UTRs fused to FLuc were expressed
in HEK293T cells in the presence of rapamycin (100 nM added to the
growth medium 30min before transfection) or a second vector express-
ing His/myc4EBP1. As an internal control, all cells were co-transfected
with a pGL3-Enhancer vector that carried the 50-UTR of b-actin fused
to an RLuc reporter. Cells were harvested 24 h post-transfection.
Normalized reporter activities were plotted with the CTRL (the two
reporter constructs alone) set at 100 (upper panels). The effect of
rapamycin and the expression of the 4EBP1 transgene were conﬁrmed
by immunoblotting with an anti-4EBP1 antibody. An immunoblot for
actin provided a loading control (lower panels). (B) HEK293T cells
were co-transfected with the S-mdm2 FLuc and b-actin RLuc
reporter plasmids 30min after addition of rapamycin at the concentra-
tions indicated (0 indicates a DMSO control). Cells were harvested 24 h
post-transfection and the normalized reporter activities plotted. The
value for the rapamycin minus control was set at 100 (upper panel).
The rapamycin response was conﬁrmed by immunoblotting using an
anti-4EBP1 antibody (lower panel). Bars indicate the SEM from trip-
licate transfections.
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Immunoblots indicated that expression from the mdm2
gene was also increased in MRC-5 cells following
rapamycin exposure. This cell line produced both the
p90 and p46 MDM2 proteins (with traces of p75) in
almost equal amounts and the expression of both was
marginally increased after 24 h of rapamycin treatment
without any marked changes in the S-mdm2 and
L-mdm2 transcript levels (Supplementary Figure S2). As
a ﬁnal control, it seemed warranted to examine what
happens in HEK293T cells during a reseeding of the
polysomal transcript populations in the presence and
absence of the drug (with 10% serum as performed in
the MRC-5 cell line). We therefore repeated the hyperton-
ic shock re-recruitment assay exactly as outlined previous-
ly (14). Sucrose gradient proﬁles demonstrated a clearly
discernable reduction in the polysomal fraction in the
presence of the drug (Figure 7A). Real-time RT–PCR
quantiﬁcation was performed across the gradient using
primer sets speciﬁc for L-mdm2, S-mdm2 and b-actin.
Evaluation of the percentage of each transcript in the
heavy polysomal fraction (5 ribosomes; this is con-
sidered an indicator of efﬁcient translational expression)
demonstrated that both mdm2 transcripts increased in the
presence of rapamycin whilst actin was slightly reduced
(Figure 7B). These results essentially mirror those
observed in the MRC-5 cell line.
DISCUSSION
The oncoprotein MDM2 acts as an ubiquitin ligase whose
main, although not exclusive, function is to target P53 for
degradation. Upon activation, P53 up-regulates the tran-
scription of MDM2 from the P2 promoter (45), establish-
ing a negative feedback loop that will limit the growth
suppressive activities of P53. A further level of complexity
arises because MDM2, via its RING domain, also binds
to the p53 mRNA. These both impair E3 ligase activity
whilst promoting p53 mRNA translation (42). In some
tumours, the over-expression of MDM2 was not
associated with an increase of RNA expression or
protein stability, suggesting that regulation was at the
level of translation. However, these studies are frequently
frustrated by the plethora of transcript isoforms. For
example, increased expression from the P2 promoter is
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Figure 3. The relative rapamycin resistance conferred by the mdm2 50-UTRs responds to the over-expression of the downstream mTORC1 effectors.
(A) The S-mdm2 FLuc and b-actin RLuc reporter plasmids were transfected into HEK293T cells with combinations of eIF4E, S6K1T389E and
S6K1T389A as indicated in the ﬁgure. Rapamycin was applied to the cells 24 h post-transfection. A series of non-treated cells provided the control
(RAP-ve). Cell extracts were prepared 24 h after drug treatment and reporter ratios were normalized to the control which was ﬁxed at 100 (upper
panel). S6K1 and eIF4E expression were conﬁrmed by immunoblotting and an anti-actin blot provided a loading control (lower panels). (B) The
assays outlined above were repeated with the L-mdm2 reporter and the constructs as indicated. The bars in both graphs indicate the SEM from
triplicate transfections.
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frequently observed generating transcripts carrying the
S-mdm2 50-UTR. This element tends to produce more
MDM2 products than the L-mdm2 50-UTR (46,47). In
addition, studies using polysomal gradient analysis
reported that the S-mdm2 was more efﬁciently translated
in tumoural compared to non-tumoural cells (48).
Therefore, a switch in promoter usage without a marked
change in overall transcript levels can have a profound
effect on the translational readout, an effect that may be
further ﬁne-tuned by the cellular context.
Clearly, mdm2 gene expression is tightly controlled at all
levels. An additional layer of complexity arises when one
examines this control in the presence of drugs that specif-
ically target cellular physiology. With regard to our own
work, the mdm2 gene was selected from a translational
proﬁling analysis performed with rapamycin.
This demonstrated that the drug reduced the overall
polysomal fraction in the cell (consistent with its global
negative effect on initiation) and this uniformly affected
the majority (96%) of cellular transcripts. However,
some mRNA populations did change (some exhibited a
hyper-sensitivity and others a hypo-sensitivity to the
drug). The mdm2 gene formed part of the latter group.
Drug-induced changes in the polysomal mRNA popula-
tions will ultimately impact on the proteomic composition
of the cell (e.g. during extended clinical therapy).
Although one of rapamycin’s principal effects is to
reduce eIF4E availability, our experiments appear to
exclude the presence of an IRES-like element in either
the S-mdm2 or L-mdm2 50-UTRs. Indeed, IRESes
are frequently cited as elements that assure continued
translational expression under stress conditions that
modulate the activity and/or availability of the cap
binding complex. They are generally associated with
genes which play key roles in cell growth control (49).
For example, the p53 50-UTR has also been reported to
carry IRES activity and its translation is auto-repressed by
the binding of the P53 protein. Upon DNA damage P53
migrates from the cytoplasm to the nucleus, thereby
de-repressing the translation of its own mRNA (50–52).
However, it is increasingly evident that other
cap-dependent mechanisms can enter into play under con-
ditions of limiting eIF4E, mechanisms that may well
explain the relative rapamycin resistance observed with
the mdm2 50-UTRs. These may involve the recruitment
of trans-acting cellular factors to the 50-UTRs that then
serve to facilitate pre-initiation complex (PIC) recruitment
via the 50-cap. These cap dependent trans-acting factors
(CTAFs by analogy to the ITAFs that regulate IRES
activity) (53) may interact with other initiation factors
(eIF4G, eIF3, etc.) or even the 40S ribosomal subunit,
thereby effectively increasing the local concentration of
these components close to the mRNA 50-end (25).
MDM2 may itself function as a CTAF as its binding to
the 50- end of the p53 mRNA promotes translation (42).
With regard to the mdm2 mRNA, one attractive CTAF
candidate was the La protein which had been reported to
modulate translational expression from the murine
mRNA (33) and has also been described to function as
an ITAF on both cellular and viral IRESes (36,54).
However, we observed no effects of over-expressed La
or the dominant negative La226-348 either in our dual
reporter assay or on endogenous MDM2 expression
levels in HEK293T cells. Other groups have also
reported differences in the translational response of the
murine and human mdm2 50-UTRs. For example, unlike
murine transcripts, the P53-activated P2 promoter in
humans generates preferentially the p90 protein product
(55). As the protein isoforms are functionally distinct this
hints at important differences in MDM2 function in these
different species.
Many aspects of our results are clearly at conﬂict with
published data. Using a cancer model system (HCT116
cell line), it was reported that rapamycin decreased
MDM2 levels by translational inhibition (29). This
group reported that the drug also induced a
P53-mediated apoptotic program. However, this is also
at conﬂict with other results that reported a down-
regulation of MDM2 levels exclusively by changes in
protein half-life (31) (in a OVCAR-3 cell line), and
studies showing the anti-apoptotic properties of
rapamycin (56,57). Our current study suggests that some
of this variation may reﬂect the conditions under which
the assays were performed. However, results in the lab
indicate that the situation may be even more complexed.
We very recently examined the rapamycin response of our
dual reporter assay in the HCT116 cellular background.
No relative resistance was observed under any of
the serum conditions tested and this correlated with
little or no change in the intracellular MDM2 levels
(Supplementary Figure S5). The reason for this discrep-
ancy with previously published data is unclear. However,
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Figure 4. The endogenous MDM2 protein levels. (A) HEK293T cells
were transfected with a pEBS-PL vector expressing a GST-tagged
La226-348 (a dominant negative deletion mutant) or an empty
plasmid vector. At 48 h post-transfection cells were either treated with
DMSO (CTRL) or rapamycin (100 nM). Extracts were prepared 24 h
later and analysed by immunoblotting using the antibodies indicated.
(B) Semi-quantitative RT–PCR was performed on cells that had been
treated or non-treated with rapamycin (lanes 1 and 3 in A) to monitor
changes in the levels of the two mdm2 50-UTRs. Actin provided the
internal control. (C) Pulse-chase experiments were performed in
HEK293T cells to monitor MDM2 stability after 24 h exposure to
rapamycin. DMSO provided the negative control. Radiolabelled cell
extracts were immunoprecipitated with an anti-MDM2 antibody and
immune complexes were recovered on protein-A sepharose beads.
Proteins were resolved by SDS–PAGE. The times of the chase and
the estimated protein half-life are indicated.
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Figure 5. What modulates the mdm2 response? (A) HEK293T cells were treated with either DMSO or rapamycin (100 nM) for 24 h in the presence
of either 2% or 10% fetal calf serum. Changes in the intracellular levels of the indicated proteins were determined by immunoblotting. (B) The
FLuc/RLuc dual reporter assay was performed as outlined in Figure 3. In experiments performed in 2% serum, cells were grown at this serum
concentration overnight prior to addition of DMSO/rapamycin (100 nM) and transfection. In the serum-free experiment, cells were grown overnight
in 10% serum before starving in serum-free medium for 8 h before DMSO/rapamycin addition and transfection. In both cases the cells were
harvested 24 h post-rapamycin addition. Reporter activities were normalized with the DMSO control in each experiment being set at 100. The
vertical arrow in the S-mdm2 panel indicates the normalized 2.5-fold increase observed in the presence of 2% serum and rapamycin.
(C) Semi-quantitative RT–PCR was performed on total RNA (500 ng) isolated from cells transfected with the reporter plasmid sets in the
presence and absence of rapamycin (indicated as + and –) under the serum concentrations indicated at the bottom of each panel. Products
were resolved on a 6% polyacrylamide gel (for the L-mdm2 FLuc transcript), an 8% polyacrylamide gel (for the S-mdm2 FLuc transcript) and
a 1% agarose gel (for the b-actin RLuc transcript). The values indicated in brackets represent the change in transcript levels observed as a
consequence of rapamycin exposure. In each gel, the lane 1 is the RT minus control. (D) The non-normalized values for the S-mdm2 Fluc and
b-actin Rluc reporters [right-hand side of (B)] are depicted graphically with the 2% serum, rapamycin negative value being set at 100. The X2.5-fold
value reﬂects the difference in the normalized reporter values observed in the right-hand side of (B). This difference effectively vanishes when the drug
is applied in the absence of serum (indicated as the lower hatched line). Note that both rapamycin and the removal of serum are negative for
expression of both reporters. The right-hand panel is an immunoblot using the antibodies indicated. The bars in all graphs indicate the SEM from
triplicate transfections.
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despite rapamycin concentrations of 1 mM and in the total
absence of serum we observed no effect on the down-
stream targets of mTORC1 (namely 4EBP1 and P-S6K1:
Supplementary Figure S5C) or changes in the readout
from the b-actin RLuc internal control (Supplementary
Figure S5B), neither did we observe any signs of a stress
response as evidenced by changes in the phosphorylation
status of eIF2a; (Supplementary Figure S5C). This cell
line is highly rapamycin resistant with an IC50>12 mM
(58), and it has been reported that drug treatment did
not alter the phosphorylation status of the rpS6 protein
(59), suggesting a relative resistance in the mTORC1.
Furthermore, these cells express active mutant forms of
K-RAS and PI3K (60), which may in part offer an explan-
ation for the absence of a serum effect. The cell speciﬁcity
of the rapamycin translational response is also apparent if
one analyses the various translational proﬁling studies
(performed in different cellular backgrounds) that have
been reported (14,61,61–64). Despite overlaps in the
various outputs, in particular the marked down-regulation
of the highly rapamycin-sensitive TOP mRNAs (65), there
was nonetheless considerable variation with some genes
being up-regulated in one background and
down-regulated in another (14).
Why would one observe an increase in MDM2 in
response to rapamycin in certain cellular contexts? It has
been reported that the MDM2 protein facilitates G1 to
S-phase transition by activation of E2F-1 (66), a
response that could serve to counteract the cell cycle
block induced by rapamycin treatment. Likewise,
evidence has accumulated linking P53 to the regulation
of mTOR activity (67). In particular, it has been
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Figure 6. (A) HEK293T cells were transferred to DMEM containing the serum concentrations indicated at the top of each column 30min prior to
transfecting with vectors expressing either L-mdm2/Fluc, S-mdm2 Fluc or an L-mdm2/Fluc construct in which the two uAUGs were changed to
GCG codons. As an internal control cells were co-transfected with the second Rluc reporter carrying the 50-UTR of b-actin. Extracts were prepared
24 h later and the dual reporter activities measured. The FLuc/RLuc ratio obtained in the presence of 10% serum was then set at 100 and the values
obtained at 2 and 0% serum were normalized relative to this. The upper panel is a series of immunoblots that follow eIF2a and phospho-eIF2a levels
under the different serum concentrations employed in the assay. (B) The normalized reporter ratios were plotted for cells co-transfected with the
b-actin RLuc and L-mdm2 uAUG1/2-ve FLuc reporter constructs in the absence (CTRL) and presence of rapamycin (100 nM) at the serum
concentrations indicated at the bottom of each column set. Bars indicate the SEM from triplicate transfections.
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demonstrated that inactivation of P53 leads to mTOR ac-
tivation via TSC1–TSC2 inhibition (68). Over-expression
of MDM2 may therefore represent a speciﬁc cell type
drug-induced response whose aim is to boost the mTOR
pathway. The only caveat in this ﬁnal scenario is our
failure to observe clear changes in P53 levels during
rapamycin treatment, despite increases in MDM2.
However, a similar phenomenon has been noted by
others (29).
Our results indicate that the relative rapamycin resist-
ance associated with the mdm2 50-UTRs is linked to the
downstream targets of mTORC1, namely S6K1 and
eIF4E, with the effect being more tightly coupled to the
activity of the former at least with respect to the S-mdm2
50-UTR. The effect of S6K1 on mRNA translation is
largely mediated via its downstream effectors. One of
these, eIF4B, plays an important role in the efﬁcient re-
cruitment of ribosomes to the mRNA (69). It assists
eIF4A-mediated unwinding of RNA secondary structure
and it has been suggested that its activity is increased by
phosphorylation (27,70). Recently, footprinting assays
have demonstrated that eIF4B is required for ribosome
binding on mRNAs containing secondary structure (71),
indicating that changes in eIF4B activity will alter the
polysomal transcript populations. However, the length
and %GC content of the b-actin and S-mdm2 50-UTRs
are similar, suggesting that the rapamycin response may
not reside simply in changes in eIF4B activity. It may be
that the S-mdm2 50-UTR is less dependent on a down-
stream S6K1 effector(s) because it can recruit other
trans-acting factors that substitute in PIC complex recruit-
ment. If such a CTAF or cap-dependent translational
enhancer (72) was to show cell speciﬁc expression
patterns, it would also provide insights into the
cell-speciﬁc responses that we observed with our dual
reporter system. Likewise, the additive effect of the
S6K1 T389A construct (Figure 3A) may just reﬂect an
enhanced negative effect on global translation that
serves to increase the pool of active PIC complexes that
the CTAF-carrying S-mdm2 50-UTR can recruit.
Our current work conﬁrms and extends the earlier
translational proﬁling studies with regard to the mdm2
gene. Despite the fact that each of the alternative mdm2
50-UTRs differ considerably in terms of primary sequence,
they each confer a rapamycin resistance phenotype
relative to the equivalent region in b-globin. One conse-
quence of this is a change in the relative polysomal abun-
dance of the mdm2 transcripts which foreshadows a
change in the relative abundance of the protein in the
cell. At least within the HEK293T cell background this
response can be modulated by growth conditions,
namely the serum concentrations employed during drug
exposure. Clearly, a more detailed molecular dissection
of the interplay between the serum signalling pathways,
mTOR and mdm2 translation is now called for. With
regard to the former, one interesting target is RSK1 as
its activity is modulated positively by serum and it
shares a common target with the S6K1, namely rpS6
(73). Furthermore, interplay between the RAS/ERK
(serum) and PI3K/mTOR pathways have already been
implicated in the selective recruitment of mRNAs to
ribosomes (1). Intriguingly, these tended to code for
proteins playing key roles in growth control and
apoptosis, features that can be assigned to MDM2.
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